Open AccessTreatment of Metastatic Renal Cell Carcinoma
Author(s) -
Igor Richter,
Josef Dvořák
Publication year - 2018
Publication title -
klinická onkologie
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.14735/amko2018110
Subject(s) - medicine , sunitinib , renal cell carcinoma , cabozantinib , temsirolimus , nivolumab , pazopanib , kidney cancer , oncology , immunotherapy , ipilimumab , cancer , sorafenib , pembrolizumab , targeted therapy , malignancy , clinical trial , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , hepatocellular carcinoma , apoptosis , biochemistry , chemistry
Renal cell cancer accounts for approximately 2-3% of all cases of malignancy. The incidence of kidney cancer in the Czech Republic is the highest in the world. Approximately 70% of renal cell carcinomas are clear-cell renal cancer. Various treatment options for metastatic renal cell cancer (mRCC) have been developed. Treatment regimens comprise antiangiogenic drugs in combination with vascular endothelial growth factor receptor inhibitors, mTOR inhibitors, and immunotherapy.